Immunicum AB announced the appointment of Leopold Bertea as Chief Technology Officer, effective as of May 5, 2022. he most recently held the position of Senior Vice President Technical Operations Europe and Member of the Cellectis Executive Committee. With previous senior roles at Novartis, LFB Biotechnologies and LFB's subsidiary CELLforCURE, Sanofi, and Ciba-Geigy, Dr. Bertea brings a total of 27 years biopharmaceutical industry experience to Immunicum.